Posted by Michael Wonder on 19 Oct 2024
Arcutis announces Health Canada approval of Zoryve (roflumilast) foam 0.3% to treat seborrheic dermatitis in individuals 9 years of age and older
18 October 2024 - Zoryve foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades.
Arcutis Biotherapeutics today announced that has received regulatory approval from Health Canada for Zoryve (roflumilast) topical foam 0.3% for the treatment of seborrheic dermatitis in patients 9 years of age and older.
